Log in  First Connection?

Acute & Chronic Kidney InjuryArchives

Factors affecting response to furosemide stress test among critically ill hypoalbuminemic patients with AKI without prior albumin infusion

 Published on 03/12/2025 |  Original article (Full-text)  | Soliman Amin Roshdy et al. | BMC Nephrology 2025; 26(1): 664

Acute Kidney Injury (AKI) is a common and serious complication that is associated with several adverse outcomes including death, need for renal replacement therapy (RRT), increased length of hospital stay, chronic kidney disease, and rising health care costs. Even mild forms of kidney injury influence...

Analysis of prognostic risk factors in critically ill elderly patients with sepsis-associated acute kidney injury

 Published on 26/11/2025 |  Original article (Full-text)  | Zeng Jiangwei et al. | BMC Nephrology 2025; 26(1): 656

Sepsis and septic shock have long been recognized as major contributors to the development of Acute Kidney Injury (AKI) in critically ill patients [1, 2]. The presence of comorbid AKI further increases the risk of sepsis and septic shock [3], highlighting the interdependent relationship between these...

Remote ischemic per-conditioning did not modulate kidney Klotho expression in acute kidney injury induced by renal ischemia/reperfusion injury

 Published on 19/11/2025 |  Original article (Full-text)  | Afshari Afsoon et al. | BMC Nephrology 2025; 26(1): 637

Renal ischemia-reperfusion injury (I/RI) is a major reason for acute kidney injury (AKI) that occurs due to renal transplantation, trauma, sepsis, and some vascular surgery [1]. Although various studies have been performed to understand the causes and molecular mechanisms of renal I/RI, it remains a...

A Strategic Roadmap to Support Communication on and Acceptance of Surrogate Endpoints: The REnal Surrogacy accEpTance in Chronic Kidney Disease (RESET CKD) Collaboration

 Published on 12/11/2025 |  Original article (Full-text)  | Garcia Sanchez Juan José et al. | Advances in Therapy 2025; 42(11): 5727-41

The development of innovative and effective treatments remains a priority [1, 2], especially for chronic and progressive diseases associated with high morbidity and mortality despite current therapies [3, 4, 5–6]. Demonstrating the definitive benefit of new interventions on patient-relevant final...